I don’t think they need to Wasa. Phase 2 trials are primarily about ensuring the safety profile, with secondary outcomes measuring efficacy and the like. These can be small number trials, possibly even as small as 6 patients. If safety concerns allayed then they can move to a Phase 2b trial to test dosages. Only in Phase 3 will many participants be required to ascertain statistical significance. With that in mind it’s certainly possible the Phase 2a trial can be run relatively cheaply.
Focus now on NNZ2591, page-25
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |